Replies to post #818107 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Gabagool,

Thanks for reposting your free medical expertise & analysis again 😶

Fact ✅️: In addition to independently peer-reviewed papers in JNS, Nature Comms, & JAMA Oncology, NWBO’s pipeline also has the validation of rigorously peer-reviewed competitive grants awarded by the 🇺🇸U.S. NIH-NCI & the 🇺🇸U.S. DoD. Those government agencies have supported & are currently supporting the clinical development of DCVax®-L & the polarized aDC1 platform.

✅ DCVax®-L
✅ DCVax®-Direct
✅ Polarized aDC1 Platform

Dr. Sheheryar Kabraji is the principal of this
PII combo trial funded by a peer-reviewed grant from the 🇺🇸U.S. DoD.

Reviewers asking for prelim data when the grant mechanism says “prelim data not required” pic.twitter.com/qrBBnIvedt

— Sheheryar Kabraji (@SKabrajiMD) March 5, 2025

Regarding the DCVax®-L PIII trial, everyone appreciates the free opinions of “Gabagool Research,” but we’ll leave the analyses & conclusions to the independent peer reviewers & the respected physicians who led the landmark trial.

Dr. Ashkan

Dr. Liau

To clarify the mis- or disinformation, & for details about the DCVax®-L PIII clinical trial, the most comprehensive resource is the independent peer review that was published in JAMA Oncology.



☑️ There are multiple trials & trial designs relevant to NWBO that include either a DCVax product or Roswell’s aDC1 platform.

☑️ Beyond the PIII ECA, DCVax®-L is also being studied in a RCT setting with placebo group.

☑️ As a matter of record, OS was always one of the endpoints for the PIII, but OS replaced PFS as the primary endpoint.

The field of immuno-oncology is advancing rapidly, with next-gen dendritic cell tech emerging as a key component in targeted, personalized, & less toxic NEXT-GEN COMBO therapies!

COMBO trials are a very recent development. Checkpoint inhibitors have only been commercially available since 2014, & DC combos with PD1 blockade technology have only recently reached PII.













“They called me Gabagool Research”



AI Fact-Checking

[tryn2]

Gee... maybe I ought to sell my half a million shares right now....🤷🙄🥸

[Doc logic]

Galzus Resesrch,

Glad you agree with NWBO then that future trials will have endpoints that lead to conditional approval early with continued followup after in indications that have lengthy OS outcomes with current available treatments. Pretrial selection markers will also create situations where patients entering are the most likely to respond thus ending trials sooner as well. Best wishes.